Pathogen reduction technology – is it time?
Identifieur interne : 000C23 ( Istex/Corpus ); précédent : 000C22; suivant : 000C24Pathogen reduction technology – is it time?
Auteurs : S. KwonSource :
- ISBT Science Series [ 1751-2816 ] ; 2016-06.
Abstract
With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (PR) technology represents a proactive approach to our blood safety paradigm. PR technology for platelets and plasma has been approved in Europe for more than 10 years. Although PR efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust PR capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since PR technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when PR technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the PR technology might prove to be beneficial.
Url:
DOI: 10.1111/voxs.12273
Links to Exploration step
ISTEX:0220A0DBF16F0C1D8B6FC44350775225EDF4F624Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathogen reduction technology – is it time?</title><author><name sortKey="Kwon, S" sort="Kwon, S" uniqKey="Kwon S" first="S." last="Kwon">S. Kwon</name><affiliation><mods:affiliation>Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>: So‐Yong Kwon, Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea.E‐mail:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sykwon@redcross.or.kr</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0220A0DBF16F0C1D8B6FC44350775225EDF4F624</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/voxs.12273</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000C23</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Pathogen reduction technology – is it time?</title><author><name sortKey="Kwon, S" sort="Kwon, S" uniqKey="Kwon S" first="S." last="Kwon">S. Kwon</name><affiliation><mods:affiliation>Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>: So‐Yong Kwon, Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea.E‐mail:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sykwon@redcross.or.kr</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">ISBT Science Series</title><title level="j" type="sub">26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</title><title level="j" type="alt">ISBT SCIENCE SERIES</title><idno type="ISSN">1751-2816</idno><idno type="eISSN">1751-2824</idno><imprint><biblScope unit="vol">11</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="117">117</biblScope><biblScope unit="page" to="122">122</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-06">2016-06</date></imprint><idno type="ISSN">1751-2816</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1751-2816</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (PR) technology represents a proactive approach to our blood safety paradigm. PR technology for platelets and plasma has been approved in Europe for more than 10 years. Although PR efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust PR capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since PR technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when PR technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the PR technology might prove to be beneficial.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>S.‐Y. Kwon</name><affiliations><json:string>Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea</json:string><json:string>: So‐Yong Kwon, Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea.E‐mail:</json:string><json:string>E-mail: sykwon@redcross.or.kr</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>blood components</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pathogen inactivation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>transfusion – transmissible infections</value></json:item></subject><articleId><json:string>VOXS12273</json:string></articleId><arkIstex>ark:/67375/WNG-TLXPBSCB-2</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (PR) technology represents a proactive approach to our blood safety paradigm. PR technology for platelets and plasma has been approved in Europe for more than 10 years. Although PR efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust PR capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since PR technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when PR technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the PR technology might prove to be beneficial.</abstract><qualityIndicators><score>9.004</score><pdfWordCount>4040</pdfWordCount><pdfCharCount>26599</pdfCharCount><pdfVersion>1.6</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>595.276 x 799.37 pts</pdfPageSize><pdfWordsPerPage>673</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>247</abstractWordCount><abstractCharCount>1813</abstractCharCount><keywordCount>3</keywordCount></qualityIndicators><title>Pathogen reduction technology – is it time?</title><genre><json:string>article</json:string></genre><host><title>ISBT Science Series</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1751-2824</json:string></doi><issn><json:string>1751-2816</json:string></issn><eissn><json:string>1751-2824</json:string></eissn><publisherId><json:string>VOXS</json:string></publisherId><volume>11</volume><issue>S2</issue><pages><first>117</first><last>122</last><total>6</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Paper</value></json:item><json:item><value>26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-TLXPBSCB-2</json:string></ark><categories><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2016</publicationDate><copyrightDate>2016</copyrightDate><doi><json:string>10.1111/voxs.12273</json:string></doi><id>0220A0DBF16F0C1D8B6FC44350775225EDF4F624</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Pathogen reduction technology – is it time?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2016 International Society of Blood Transfusion</licence></availability><date type="published" when="2016-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Pathogen reduction technology – is it time?</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">S.‐Y.</forename><surname>Kwon</surname></persName><affiliation><orgName type="division">Korean Red Cross</orgName>
<orgName type="institution">Seoul Nambu Blood Center</orgName>
<address><settlement>Seoul</settlement>
<country key="KP" xml:lang="en">KOREA, DEMOCRATIC PEOPLE'S REPUBLIC
OF</country></address></affiliation></author><idno type="istex">0220A0DBF16F0C1D8B6FC44350775225EDF4F624</idno><idno type="ark">ark:/67375/WNG-TLXPBSCB-2</idno><idno type="DOI">10.1111/voxs.12273</idno><idno type="unit">VOXS12273</idno><idno type="toTypesetVersion">file:VOXS.VOXS12273.pdf</idno></analytic><monogr><title level="j" type="main">ISBT Science Series</title><title level="j" type="sub">26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</title><title level="j" type="alt">ISBT SCIENCE SERIES</title><idno type="pISSN">1751-2816</idno><idno type="eISSN">1751-2824</idno><idno type="book-DOI">10.1111/(ISSN)1751-2824</idno><idno type="book-part-DOI">10.1111/voxs.2016.11.issue-S2</idno><idno type="product">VOXS</idno><imprint><biblScope unit="vol">11</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="117">117</biblScope><biblScope unit="page" to="122">122</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract style="main" xml:id="voxs12273-abs-0001"><p>With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (<hi rend="fc">PR</hi>) technology represents a proactive approach to our blood safety paradigm. <hi rend="fc">PR</hi> technology for platelets and plasma has been approved in Europe for more than 10 years. Although <hi rend="fc">PR</hi> efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust <hi rend="fc">PR</hi> capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since <hi rend="fc">PR</hi> technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when <hi rend="fc">PR</hi> technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the <hi rend="fc">PR</hi> technology might prove to be beneficial.</p></abstract><textClass><keywords><term xml:id="voxs12273-kwd-0001">blood components</term><term xml:id="voxs12273-kwd-0002">pathogen inactivation</term><term xml:id="voxs12273-kwd-0003">transfusion – transmissible infections</term></keywords><keywords rend="articleCategory"><term>Original Paper</term></keywords><keywords rend="tocHeading1"><term>26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="voxs12273" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1751-2824</doi><issn type="print">1751-2816</issn><issn type="electronic">1751-2824</issn><idGroup><id type="product" value="VOXS"></id></idGroup><titleGroup><title sort="ISBT SCIENCE SERIES" type="main">ISBT Science Series</title><title type="short">VOXS</title></titleGroup></publicationMeta><publicationMeta level="part" position="18"><doi origin="wiley">10.1111/voxs.2016.11.issue-S2</doi><titleGroup><title type="specialIssueTitle">26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</title></titleGroup><copyright ownership="thirdParty">Copyright ISBT Science Series © 2016 International Society of Blood Transfusion</copyright><numberingGroup><numbering number="11" type="journalVolume">11</numbering><numbering type="journalIssue">S2</numbering></numberingGroup><coverDate startDate="2016-06">June 2016</coverDate></publicationMeta><publicationMeta level="unit" position="220" status="forIssue" type="article"><doi>10.1111/voxs.12273</doi><idGroup><id type="unit" value="VOXS12273"></id></idGroup><countGroup><count number="6" type="pageTotal"></count></countGroup><titleGroup><title type="articleCategory">Original Paper<link href="#voxs12273-note-0101"></link></title><title type="tocHeading1">26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</title></titleGroup><copyright ownership="thirdParty">© 2016 International Society of Blood Transfusion</copyright><eventGroup><event agent="SPS" date="2016-02-16" type="xmlCreated"></event><event agent="SPS" date="2016-12-24" type="xmlCorrected"></event><event type="firstOnline" date="2016-06-28"></event><event type="publishedOnlineFinalForm" date="2016-06-28"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:5.0.6 mode:FullText" date="2017-02-10"></event></eventGroup><numberingGroup><numbering type="pageFirst">117</numbering><numbering type="pageLast">122</numbering></numberingGroup><correspondenceTo><lineatedText><line><i>Correspondence</i>: So‐Yong Kwon, Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea.</line><line>E‐mail: <email>sykwon@redcross.or.kr</email></line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:VOXS.VOXS12273.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Pathogen reduction technology – is it time?</title><title type="shortAuthors">S.‐Y. Kwon</title></titleGroup><creators><creator affiliationRef="#voxs12273-aff-0001" corresponding="yes" creatorRole="author" xml:id="voxs12273-cr-0001"><personName><givenNames>S.‐Y.</givenNames> <familyName>Kwon</familyName></personName></creator></creators><affiliationGroup><affiliation countryCode="KP" type="organization" xml:id="voxs12273-aff-0001"><orgDiv>Korean Red Cross</orgDiv> <orgName>Seoul Nambu Blood Center</orgName> <address><city>Seoul</city> <country>Korea</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="voxs12273-kwd-0001">blood components</keyword><keyword xml:id="voxs12273-kwd-0002">pathogen inactivation</keyword><keyword xml:id="voxs12273-kwd-0003">transfusion – transmissible infections</keyword></keywordGroup><abstractGroup><abstract type="main" xml:id="voxs12273-abs-0001"><p>With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (<fc>PR</fc>) technology represents a proactive approach to our blood safety paradigm. <fc>PR</fc> technology for platelets and plasma has been approved in Europe for more than 10 years. Although <fc>PR</fc> efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust <fc>PR</fc> capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since <fc>PR</fc> technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when <fc>PR</fc> technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the <fc>PR</fc> technology might prove to be beneficial.</p></abstract></abstractGroup></contentMeta><noteGroup xml:id="voxs12273-ntgp-0101"><note xml:id="voxs12273-note-0101">3A‐PL4‐02</note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Pathogen reduction technology – is it time?</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pathogen reduction technology – is it time?</title></titleInfo><name type="personal"><namePart type="given">S.‐Y.</namePart><namePart type="family">Kwon</namePart><affiliation>Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea</affiliation><affiliation>: So‐Yong Kwon, Korean Red Cross, Seoul Nambu Blood Center, Seoul, Korea.E‐mail:</affiliation><affiliation>E-mail: sykwon@redcross.or.kr</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2016-06</dateIssued><dateCreated encoding="w3cdtf">2016-02-16</dateCreated><copyrightDate encoding="w3cdtf">2016</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract>With the application of stringent donor selection criteria and screening tests, the risk of the so‐called traditional transfusion‐transmitted infections has dramatically decreased. However, breakthrough cases are still being reported. Known pathogens that are not screened for and emerging pathogens represent a constant threat. Moreover, bacterial contamination remains the major infectious risk in blood transfusion. Pathogen reduction (PR) technology represents a proactive approach to our blood safety paradigm. PR technology for platelets and plasma has been approved in Europe for more than 10 years. Although PR efficacy against non‐enveloped viruses and spore forming bacteria is less satisfactory, these technologies show a robust PR capability for a broad spectrum of pathogens. According to current data, transfusion reactions after transfusion of treated platelets are comparable to that of non‐treated platelets and transfusion of treated platelets does not increase bleeding. Since PR technologies target nucleic acids, they inactivate leucocytes, thereby preventing non‐infectious risks like transfusion‐associated graft‐versus‐host disease and febrile non‐haemolytic transfusion reactions. Despite the multiple risks averted through pathogen reduction, the cost to implement these technologies remains a major issue. On the other hand, pathogen reduction could be an alternative to bacterial screening and gamma irradiation. Furthermore, cessation of some of the current screening items and modification of some donor exclusion criteria might be possible, especially when PR technology for red blood cells or whole blood becomes available. Therefore, if we consider all correlated efforts involved to make blood transfusion safe, the introduction of the PR technology might prove to be beneficial.</abstract><subject><genre>keywords</genre><topic>blood components</topic><topic>pathogen inactivation</topic><topic>transfusion – transmissible infections</topic></subject><relatedItem type="host"><titleInfo><title>ISBT Science Series</title></titleInfo><titleInfo type="abbreviated"><title>VOXS</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Paper</topic><topic>26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</topic></subject><identifier type="ISSN">1751-2816</identifier><identifier type="eISSN">1751-2824</identifier><identifier type="DOI">10.1111/(ISSN)1751-2824</identifier><identifier type="PublisherID">VOXS</identifier><part><date>2016</date><detail type="title"><title>26th Regional Congress of the International Society of Blood Transfusion Nusa Dua, Bali, Indonesia November 14–16, 2015</title></detail><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><extent unit="pages"><start>117</start><end>122</end><total>6</total></extent></part></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0001"><titleInfo><title>Transfusion‐transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis</title></titleInfo><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Busch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Busch MP: Transfusion‐transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 2006; 46:1624–1640</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1624</start><end>1640</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1624</start><end>1640</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0002"><titleInfo><title>International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009</title></titleInfo><name type="personal"><namePart type="given">WK</namePart><namePart type="family">Roth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Busch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Schuller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roth WK, Busch MP, Schuller A, et al.: International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012; 102:82–90</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>82</start><end>90</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>82</start><end>90</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0003"><titleInfo><title>Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Phelps</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Robbins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Liberti</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Phelps R, Robbins K, Liberti T, et al.: Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004; 44:929–933</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>929</start><end>933</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>929</start><end>933</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0004"><titleInfo><title>First report of human immunodeficiency virus transmission via an RNA‐screened blood donation</title></titleInfo><name type="personal"><namePart type="given">EL</namePart><namePart type="family">Delwart</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ND</namePart><namePart type="family">Kalmin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TS</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Delwart EL, Kalmin ND, Jones TS, et al.: First report of human immunodeficiency virus transmission via an RNA‐screened blood donation. Vox Sang 2004; 86:171–177</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>171</start><end>177</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>171</start><end>177</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0005"><titleInfo><title>Failure and success of HIV tests for the prevention of HIV‐1 transmission by blood and tissue donations</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Najioullah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Barlet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Renaudier</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Najioullah F, Barlet V, Renaudier P, et al.: Failure and success of HIV tests for the prevention of HIV‐1 transmission by blood and tissue donations. J Med Virol 2004; 73:347–349</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>347</start><end>349</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Virol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>347</start><end>349</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0006"><titleInfo><title>First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Kretzschmar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Chudy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Nübling</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kretzschmar E, Chudy M, Nübling CM, et al.: First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007; 92:209–301</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>209</start><end>301</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>209</start><end>301</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0007"><titleInfo><title>First transmission of human immunodeficiency virus type 1 by a cellular blood product after mandatory nucleic acid screening in Germany</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schmidt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Korn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Nübling</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schmidt M, Korn K, Nübling CM, et al.: First transmission of human immunodeficiency virus type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion2009;49:1836–1844</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1836</start><end>1844</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1836</start><end>1844</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0008"><titleInfo><title>First report of human immunodeficiency virus transmission via a blood donation that tested negative by 20‐minipool nucleic acid amplification in Japan</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Sobata</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Shinohara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Matsumoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sobata R, Shinohara N, Matsumoto C, et al.: First report of human immunodeficiency virus transmission via a blood donation that tested negative by 20‐minipool nucleic acid amplification in Japan. Transfusion 2014; 54:2361–2362</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>2361</start><end>2362</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>2361</start><end>2362</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0009"><titleInfo><title>535 infections newly identified in 2003</title></titleInfo><name type="corporate"><namePart>Korea Centers for Disease Control & Prevention</namePart></name><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0010"><titleInfo><title>Considerations for options to further reduce the risk of bacterial contamination in platelets</title></titleInfo><name type="corporate"><namePart>US Food and Drug Administration</namePart></name><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0011"><titleInfo><title>Bacterial contamination</title></titleInfo><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Benjamin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Benjamin RJ: Bacterial contamination. ISBT Sci Ser 2014; 9:37–43</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>37</start><end>43</end></extent></part><relatedItem type="host"><titleInfo><title>ISBT Sci Ser</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>37</start><end>43</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0012"><titleInfo><title>Six years’ experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false‐negative results</title></titleInfo><name type="personal"><namePart type="given">CP</namePart><namePart type="family">Larsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Ezligini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NO</namePart><namePart type="family">Hermansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Larsen CP, Ezligini F, Hermansen NO, et al.: Six years’ experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false‐negative results. Vox Sang 2005; 88:93–97</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>93</start><end>97</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>93</start><end>97</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0013"><titleInfo><title>The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two‐bottle culture systems and an estimation of false‐negative culture rates</title></titleInfo><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Benjamin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Wagner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Benjamin RJ, Wagner SJ: The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two‐bottle culture systems and an estimation of false‐negative culture rates. Transfusion 2007; 47:1381–1389</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1381</start><end>1389</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1381</start><end>1389</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0014"><titleInfo><title>Fatal false‐negative transfusion infection involving a buffy coat platelet pool contaminated with biofilm‐positive Staphylococcus epidermidis: a case report</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Pagotto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Hannach</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kou Y, Pagotto F, Hannach B, et al.: Fatal false‐negative transfusion infection involving a buffy coat platelet pool contaminated with biofilm‐positive Staphylococcus epidermidis: a case report. Transfusion 2015; 55:2384–2389</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>2384</start><end>2389</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>2384</start><end>2389</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0015"><titleInfo><title>Investigation of transfusion adverse reactions in Korea from 2007 to 2012. Public Health Weekly Report</title></titleInfo><name type="corporate"><namePart>Korea Centers for Disease Control & Prevention</namePart></name><genre>journal-article</genre><note type="citation/reference">Korea Centers for Disease Control & Prevention: Investigation of transfusion adverse reactions in Korea from 2007 to 2012. Public Health Weekly Report. KCDC 2012; 5:937–941</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>937</start><end>941</end></extent></part><relatedItem type="host"><titleInfo><title>KCDC</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>937</start><end>941</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0016"><titleInfo><title>Middle East respiratory syndrome coronavirus (MERS‐CoV) outbreak in South Korea: risk management at the Korean Red Cross Seoul Nambu blood center</title></titleInfo><name type="personal"><namePart type="given">SY</namePart><namePart type="family">Kwon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">EH</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HS</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kwon SY, EH L, Kim HS, et al.: Middle East respiratory syndrome coronavirus (MERS‐CoV) outbreak in South Korea: risk management at the Korean Red Cross Seoul Nambu blood center. Vox Sang 2015; 109(Suppl 2):18–19</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 2</number></detail><extent unit="pages"><start>18</start><end>19</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 2</number></detail><extent unit="pages"><start>18</start><end>19</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0017"><titleInfo><title>Pathogen inactivation: a new paradigm for blood safety</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">McCullough</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McCullough J: Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007; 47:2180–2184</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>2180</start><end>2184</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>2180</start><end>2184</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0018"><titleInfo><title>Pathogen reduction: a precautionary principle paradigm</title></titleInfo><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Alter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alter HJ: Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22:97–102</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>97</start><end>102</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Rev</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>97</start><end>102</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0019"><titleInfo><title>Advisory committee on the safety of blood, tissues and organs: Pathogen inactivation of platelets</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0020"><titleInfo><title>Chemical and biological mechanisms of pathogen reduction technologies</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Mundt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Rouse</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Van den Bossche</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mundt JM, Rouse L, Van den Bossche J, et al.: Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014; 90:957–964</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>957</start><end>964</end></extent></part><relatedItem type="host"><titleInfo><title>Photochem Photobiol</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>957</start><end>964</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0021"><titleInfo><title>FDA approach to evaluation of pathogen reduction technology</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Epstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JG</namePart><namePart type="family">Vostal</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Epstein JS, Vostal JG: FDA approach to evaluation of pathogen reduction technology. Transfusion 2003; 43:1347–1350</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1347</start><end>1350</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1347</start><end>1350</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0022"><titleInfo><title>Keeping blood transfusion safe from West Nile virus: American Red Cross experience, 2003 to 2012</title></titleInfo><name type="personal"><namePart type="given">RY</namePart><namePart type="family">Dodd</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Foster</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Stramer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dodd RY, Foster GA, Stramer SL: Keeping blood transfusion safe from West Nile virus: American Red Cross experience, 2003 to 2012. Transfus Med Rev 2015; 29:153–161</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>153</start><end>161</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Rev</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>153</start><end>161</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0023"><titleInfo><title>Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light</title></titleInfo><name type="personal"><namePart type="given">PH</namePart><namePart type="family">Ruane</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Edrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Gampp</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruane PH, Edrich R, Gampp D, et al.: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877–885</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>877</start><end>885</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>877</start><end>885</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0024"><titleInfo><title>Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CV</namePart><namePart type="family">Hanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Alter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin L, Hanson CV, Alter HJ, et al.: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light. Transfusion 2005; 45:580–590</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>580</start><end>590</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>580</start><end>590</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0025"><titleInfo><title>The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends</title></titleInfo><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Edrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodrich RP, Edrich RA, Li J, et al.: The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35:5–17</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>5</start><end>17</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Apher Sci</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>5</start><end>17</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0026"><titleInfo><title>Inactivation of a European strain of West Nile virus in single‐donor platelet concentrate using the Intercept Blood System</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Gallian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Vignolo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Dombey</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gallian P, Vignolo C, Dombey AM, et al.: Inactivation of a European strain of West Nile virus in single‐donor platelet concentrate using the Intercept Blood System. Vox Sang 2006; 91:345–347</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>345</start><end>347</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>345</start><end>347</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0027"><titleInfo><title>Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Sawyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Hanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Castro</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sawyer L, Hanson D, Castro G, et al.: Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47:1062–1070</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1062</start><end>1070</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1062</start><end>1070</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0028"><titleInfo><title>Emerging infectious disease agents and their potential threat to transfusion safety</title></titleInfo><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Stramer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FB</namePart><namePart type="family">Hollinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Katz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stramer SL, Hollinger FB, Katz LM, et al.: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49:1S–29S</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1S</start><end>29S</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1S</start><end>29S</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0029"><titleInfo><title>Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non‐leukoreduced platelet‐rich plasma‐derived platelets suspended in plasma</title></titleInfo><name type="personal"><namePart type="given">SY</namePart><namePart type="family">Kwon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IS</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JE</namePart><namePart type="family">Bae</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kwon SY, Kim IS, Bae JE, et al.: Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non‐leukoreduced platelet‐rich plasma‐derived platelets suspended in plasma. Vox Sang 2014; 107:254–260</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>254</start><end>260</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>254</start><end>260</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0030"><titleInfo><title>Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Dikeman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Molini</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin L, Dikeman R, Molini B, et al.: Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44:1496–1504</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1496</start><end>1504</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1496</start><end>1504</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0031"><titleInfo><title>Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long‐wavelength UV</title></titleInfo><name type="personal"><namePart type="given">VW</namePart><namePart type="family">Van</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LK</namePart><namePart type="family">Barrett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RT</namePart><namePart type="family">Eastman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van VW, Barrett LK, Eastman RT, et al.: Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long‐wavelength UV. Antimicrob Agents Chemother 2003; 47:475–479</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>475</start><end>479</end></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>475</start><end>479</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0032"><titleInfo><title>Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long‐wavelength ultraviolet irradiation</title></titleInfo><name type="personal"><namePart type="given">RT</namePart><namePart type="family">Eastman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LK</namePart><namePart type="family">Barrett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Dupuis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eastman RT, Barrett LK, Dupuis K, et al.: Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long‐wavelength ultraviolet irradiation. Transfusion 2005; 45:1459–1463</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1459</start><end>1463</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1459</start><end>1463</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0033"><titleInfo><title>Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light</title></titleInfo><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Cardo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FJ</namePart><namePart type="family">Rentas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Ketchum</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cardo LJ, Rentas FJ, Ketchum L, et al.: Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90:85–91</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>85</start><end>91</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>90</number></detail><extent unit="pages"><start>85</start><end>91</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0034"><titleInfo><title>Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Singh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LS</namePart><namePart type="family">Sawyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LS</namePart><namePart type="family">Pinkoski</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Singh Y, Sawyer LS, Pinkoski LS, et al.: Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46:1168–1177</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1168</start><end>1177</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1168</start><end>1177</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0035"><titleInfo><title>The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (Intercept) for inactivation of Trypanosoma cruzi in pooled buffy‐coat platelets</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Castro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Gironés</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Bueno</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Castro E, Gironés N, Bueno JL, et al.: The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (Intercept) for inactivation of Trypanosoma cruzi in pooled buffy‐coat platelets. Transfusion 2007; 47:434–441</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>434</start><end>441</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>434</start><end>441</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0036"><titleInfo><title>Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light</title></titleInfo><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Cardo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Salata</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Mendez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cardo LJ, Salata J, Mendez J, et al.: Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37:131–137</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>131</start><end>137</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Apher Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>131</start><end>137</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0037"><titleInfo><title>Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Grellier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Benach</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Labaied</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grellier P, Benach J, Labaied M, et al.: Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008; 48:1676–1684</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1676</start><end>1684</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1676</start><end>1684</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0038"><titleInfo><title>Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Tonnetti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MC</namePart><namePart type="family">Proctor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HL</namePart><namePart type="family">Reddy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tonnetti L, Proctor MC, Reddy HL, et al.: Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50:1019–1027</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>1019</start><end>1027</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>1019</start><end>1027</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0039"><titleInfo><title>Inactivation of Plasmodium spp In plasma and platelet concentrates using riboflavin and ultraviolet light.</title></titleInfo><name type="personal"><namePart type="given">SD</namePart><namePart type="family">Keil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Kiser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Sullivan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Keil SD, Kiser P, Sullivan JJ, et al.: Inactivation of Plasmodium spp In plasma and platelet concentrates using riboflavin and ultraviolet light.. Transfusion 2013; 53:2278–2286</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>2278</start><end>2286</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>2278</start><end>2286</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0040"><titleInfo><title>Einführung der Pathogeninaktivierung für Thrombozytenkonzentrate in der Schweiz</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Jutzi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Rüesch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BM</namePart><namePart type="family">Taleghani</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jutzi M, Rüesch M, Taleghani BM: Einführung der Pathogeninaktivierung für Thrombozytenkonzentrate in der Schweiz. Schweiz Med Forum 2013; 13:222–226</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>222</start><end>226</end></extent></part><relatedItem type="host"><titleInfo><title>Schweiz Med Forum</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>222</start><end>226</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0041"><titleInfo><title>Pathogen‐reduced platelets for the prevention of bleeding (review)</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Butler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Doree</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Estcourt</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Butler C, Doree C, Estcourt LJ, et al.: Pathogen‐reduced platelets for the prevention of bleeding (review). Cochrane Database Syst Rev 2013; 3:CD009072</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>CD009072</start></extent></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst Rev</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>CD009072</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0042"><titleInfo><title>A prospective, active haemovigilance study with combined cohort analysis of 19175 transfusions of platelet components prepared with amotosalen‐UVA photochemical treatment</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Knutson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Osselaer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Pierelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Knutson F, Osselaer J, Pierelli L, et al.: A prospective, active haemovigilance study with combined cohort analysis of 19175 transfusions of platelet components prepared with amotosalen‐UVA photochemical treatment. Vox Sang 2015; 109:343–352</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>343</start><end>352</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>343</start><end>352</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0043"><titleInfo><title>Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction</title></titleInfo><name type="personal"><namePart type="given">JP</namePart><namePart type="family">AuBuchon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Herschel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Roger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">AuBuchon JP, Herschel L, Roger J, et al.: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45:1335–1341</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1335</start><end>1341</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1335</start><end>1341</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0044"><titleInfo><title>Reducing the financial impact of pathogen inactivation technology for platelet components: our experience</title></titleInfo><name type="personal"><namePart type="given">EG</namePart><namePart type="family">Llobera</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Jimenez‐Marco</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Galmes‐Trueba</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Llobera EG, Jimenez‐Marco T, Galmes‐Trueba A, et al.: Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014; 54:158–168</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>158</start><end>168</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>158</start><end>168</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0045"><titleInfo><title>Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet light</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Snyder</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Raife</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Snyder E, Raife T, Lin L, et al.: Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet light. Transfusion 2004; 44:1732–1740</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1732</start><end>1740</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1732</start><end>1740</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0046"><titleInfo><title>Properties of pathogen‐inactivated plasma components</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Prowse</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prowse C: Properties of pathogen‐inactivated plasma components. Transfus Med Rev 2009; 23:124–133</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>124</start><end>133</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Rev</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>124</start><end>133</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0047"><titleInfo><title>Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cid</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Ramiro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Martínez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cid J, Ramiro L, Martínez N, et al.: Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfus Apher Sci 2008; 39:115–121</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>115</start><end>121</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Apher Sci</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>115</start><end>121</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0048"><titleInfo><title>Pathogen inactivation: coming of age</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Lozano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cid</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lozano M, Cid J: Pathogen inactivation: coming of age. Curr Opin Hematol 2013; 20:540–545</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>540</start><end>545</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Hematol</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>540</start><end>545</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0049"><titleInfo><title>Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA</title></titleInfo><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Grass</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Hei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Metchette</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grass JA, Hei DJ, Metchette K, et al.: Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91:2180–2188</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>2180</start><end>2188</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>2180</start><end>2188</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0050"><titleInfo><title>Prevention of transfusion‐associated graft‐versus‐host disease by photochemical treatment</title></titleInfo><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Grass</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Wafa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Reames</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grass JA, Wafa T, Reames A, et al.: Prevention of transfusion‐associated graft‐versus‐host disease by photochemical treatment. Blood 1999; 93:3140–3147</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>3140</start><end>3147</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>3140</start><end>3147</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0051"><titleInfo><title>Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft‐versus‐host disease in Rag2−/−γc−/− double knockout mice</title></titleInfo><name type="personal"><namePart type="given">LD</namePart><namePart type="family">Fast</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">DiLeone</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Cardarelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fast LD, DiLeone G, Cardarelli G, et al.: Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft‐versus‐host disease in Rag2−/−γc−/− double knockout mice. Transfusion 2006; 46:1553–1560</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1553</start><end>1560</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1553</start><end>1560</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0052"><titleInfo><title>Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion‐associated graft‐versus‐host disease?</title></titleInfo><name type="personal"><namePart type="given">LD</namePart><namePart type="family">Fast</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Nevola</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Tavares</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fast LD, Nevola M, Tavares J, et al.: Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion‐associated graft‐versus‐host disease? Transfusion 2013; 53:373–381</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>373</start><end>381</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>373</start><end>381</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0053"><titleInfo><title>Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Hei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Grass</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hei DJ, Grass L, Lin L, et al.: Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39:239–248</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>239</start><end>248</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>239</start><end>248</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="voxs12273-cit-0054"><titleInfo><title>Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period</title></titleInfo><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Cazenave</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Isola</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Walle</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cazenave JP, Isola H, Walle RC, et al.: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period. Transfusion 2011; 51:622–629</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>622</start><end>629</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>622</start><end>629</end></extent></part></relatedItem></relatedItem><identifier type="istex">0220A0DBF16F0C1D8B6FC44350775225EDF4F624</identifier><identifier type="ark">ark:/67375/WNG-TLXPBSCB-2</identifier><identifier type="DOI">10.1111/voxs.12273</identifier><identifier type="ArticleID">VOXS12273</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright ISBT Science Series © 2016 International Society of Blood Transfusion© 2016 International Society of Blood Transfusion</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TLXPBSCB-2/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000C23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0220A0DBF16F0C1D8B6FC44350775225EDF4F624
|texte= Pathogen reduction technology – is it time?
}}
| This area was generated with Dilib version V0.6.33. |  |